Results for tag: "Vyndaqel"

Vyndaqel (tafamidis meglumine) is a drug used to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a rare, progressive, and fatal genetic disorder of the heart. It is the first and only approved treatment for ATTR-CM in the United States and Europe. Vyndaqel is a small molecule drug that binds to transthyretin, a protein found in the blood, and stabilizes it, preventing it from forming amyloid fibrils that can damage the heart. The Vyndaqel market is a rapidly growing segment of the Central Nervous System (CNS) drugs market. It is a specialized market, as Vyndaqel is the only approved treatment for ATTR-CM. The market is expected to grow due to the increasing prevalence of ATTR-CM and the need for effective treatments. Companies in the Vyndaqel market include Pfizer, which manufactures and markets the drug, as well as other pharmaceutical companies that are researching and developing treatments for ATTR-CM. These companies include Ionis Pharmaceuticals, Alnylam Pharmaceuticals, and Proteostasis Therapeutics. Show Less Read more